VivoSeq
Infectious Disease

Respiratory Syncytial Virus Infection

15

Pipeline Programs↗

0

Active Trials↗

7

Companies Involved↗

Respiratory Syncytial Virus Infection is an emerging landscape with 15 programs across 7 companies. The most active players are Johnson & Johnson, Gilead, Enanta Pharmaceuticals, Inc. 3 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

89/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

3 programs

Phase 2Gilead logo

Gilead

1 program

Phase 2E

Enanta Pharmaceuticals, Inc

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2Sanofi logo

Sanofi

2 programs

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

82%

Small molecule

9 of 11 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody19%Vaccine19%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 94% of 16 pipeline programs.

Analysis

Trial Status

9

clinical trials

Completed8 · 89%
Terminated1 · 11%

Clinical Trials

Trial Activity

9 trials

Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children
Completed·AAbbott·Phase 2/3·NCT01006629·100 enrolled
A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model
Completed·EEnanta Pharmaceuticals, Inc·Phase 2·NCT06170242·142 enrolled
Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older Adults
Completed·RResearch Institute of Influenza, Russia·Phase 2·NCT06890429·120 enrolled
An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT03334695·64 enrolled
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
Completed·Gilead logoGilead·Phase 2·NCT02254408·189 enrolled
A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT03332459·7 enrolled
Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT02387606·66 enrolled
The Development of a Human Model of Respiratory Syncytial Virus Infection
Completed·IImperial College London·N/A·NCT01349543·58 enrolled
Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection
Terminated·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT03656510·246 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)